Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sang Yi is Group President, Asia Pacific at Zimmer Biomet. OQRO lists 16 transactions filed with the SEC under this name, the latest on Jun 2, 2026, each linked to the official Form 4.
Group President, Asia Pacific
Disclosures on record
16
Companies involved
1
As of the latest filing on , Sang Yi reported holding 27,251 shares of Zimmer Biomet (ZBH), worth about $2.76M at the last close of $101 (Nov 20, 2026). In the last 12 months, Sang Yi sold $510K in 3 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zimmer Biomet ZBH | 27,251 | 27K direct | $101 | $2.76M | May 29, 2026 |
Is this Sang Yi’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Zimmer BiometZBH
16 disclosures · Jun 2025 – Jun 2026 · 6 sold
May 29, 2026Sold~$347Kdisclosed Jun 2
DetailsOfficial recordMay 29, 2026Sold~$66Kdisclosed Jun 2
DetailsMar 6, 20267,050disclosed Mar 10
DetailsOfficial recordMar 6, 20262,364disclosed Mar 10
DetailsOfficial recordMar 6, 20267,050disclosed Mar 10
DetailsOfficial recordMar 6, 20262,364disclosed Mar 10
DetailsOfficial recordFeb 25, 20262,785disclosed Feb 27
DetailsOfficial recordFeb 25, 20262,785disclosed Feb 27
DetailsOfficial recordFeb 20, 20269,043disclosed Feb 25
DetailsOfficial recordFeb 20, 20262,382disclosed Feb 25
DetailsOfficial recordFeb 20, 20262,382disclosed Feb 25
DetailsOfficial recordFeb 19, 20267,050disclosed Feb 23
DetailsOfficial recordFeb 12, 2026Sold~$96Kdisclosed Feb 17
DetailsOfficial recordSep 11, 2025Sold~$124Kdisclosed Sep 15
DetailsOfficial recordJun 13, 2025Sold~$74Kdisclosed Jun 17
DetailsOfficial recordJun 11, 2025Sold~$95Kdisclosed Jun 13
DetailsOfficial recordSang Yi has no open-market purchase on record since 2017. Sales in each of the last 3 years.
Sang Yi reported 0 open-market purchases and 19 sales since 2017; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $510K3×3 trades |
| 2025 | — | $293K3×3 trades |
| 2024 | — | $1.69M2×2 trades |
| 2021 | — | $348K2×2 trades |
| 2020 | — | $559K2×2 trades |
| 2019 | — | $69K2×2 trades |
| 2017 | — | $2.21M5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 29, 2026, Sang Yi reported holding 27,251 shares of Zimmer Biomet (ZBH). At the last close of $101 on Nov 20, 2026, that is about $2.76M. This is the stake disclosed in filings, not a net worth.
No public filing gives Sang Yi's net worth. What SEC Form 4 shows is the stock stake: 27,251 shares of Zimmer Biomet (ZBH), about $2.76M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Sang Yi reported 3 open-market sales worth $510K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Sang Yi has no open-market purchase on record since 2017. Sales in each of the last 3 years.
In SEC filings since 2017: no open-market purchase is on record; the latest open-market sale is from 2026.
Zimmer Biomet (ZBH), from 2017 to 2026: 0 purchases and 19 sales.
Sang Yi reported 0 open-market purchases and 19 sales here, 2017 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.